Multiplex Assay Kit for C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array)

CTRP9; C1QTNF9A; AQL1; Complement C1q and tumor necrosis factor-related protein 9A

Specificity

This assay has high sensitivity and excellent specificity for detection of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array).
No significant cross-reactivity or interference between C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 99-105 102
EDTA plasma(n=5) 88-96 92
heparin plasma(n=5) 79-93 81

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 88-97% 92-105% 92-102% 96-105%
EDTA plasma(n=5) 78-101% 82-93% 84-104% 79-93%
heparin plasma(n=5) 81-98% 85-93% 98-105% 91-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity

Assay procedure summary

1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Int J Obes (Lond). Association of serum C1q/TNF-Related Protein-9 (CTRP9) concentration with visceral adiposity and metabolic syndrome in humans. Pubmed: 24357853
J Clin Endocrinol Metab.? Association of Serum C1q/TNF-Related Protein-9 Concentration With Arterial Stiffness in Subjects With Type 2 Diabetes Pubmed:25105737
J Clin Endocrinol Metab.  C1q/TNF-Related Protein-9 (CTRP9) Levels Are Associated With Obesity and Decrease Following Weight Loss Surgery Pubmed:26982010
PLoS One. Circulating C1q complement/TNF-related protein (CTRP) 1, CTRP9, CTRP12 and CTRP13 concentrations in Type 2 diabetes mellitus: In vivo regulation by glucose. pubmed:28207876
Journal of Diabetes Research Plasma C1q/TNF-Related Protein-9 Levels Are Associated with Atherosclerosis in Patients withType 2 Diabetes without Renal Dysfunction. pubmed:28070523
diabetes research and clinical practice Circulating CTRP9 levels are increased in patients with newly diagnosed type 2 diabetes and correlated with insulin resistance pubmed:28743061
PLoS One Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery … Pubmed:29381773
archives of insect biochemistry and physiology Effect of a single bout of resistance exercise on zinc-α2-glycoprotein Pubmed: 31686532
J Diabetes Investig Association of serum CTRP9 levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus 33417302
Neurol Ther Association Between Serum C1q Tumor Necrosis Factor-Related Protein 9 and the Clinical Characteristics and Prognosis of Ischemic Stroke 34727346
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
EPR877Mu61 Eukaryotic C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) Positive Control; Immunogen; SDS-PAGE; WB.
SER877Mu ELISA Kit for C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) Enzyme-linked immunosorbent assay for Antigen Detection.
LMR877Mu Multiplex Assay Kit for C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.
CMR877Mu Multiplex Assay Kit for C1q And Tumor Necrosis Factor Related Protein 9 (C1QTNF9) ,etc. by CBA (Cytometric Bead Array) FLIA Kit for Antigen Detection.